Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review

Fabiola Atzeni*, Elisabetta Grillo, Ignazio F. Masala, Piercarlo Sarzi-Puttini, Gareth T. Jones

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

3 Citations (Scopus)


Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.

Original languageEnglish
Pages (from-to)154-155
Number of pages2
JournalIsrael medical association journal
Issue number3-4
Publication statusPublished - Mar 2016


  • ankylosing spondylitis (AS)
  • psoriatic arthritis (PsA)
  • anti-tumor necrosis factor (TNF)
  • interstitial lung disease (ILD)
  • pulmonary fibrosis

Cite this